TAKEDA MANUFACTURING PLANT WILL INCREASE U.S. VITAMIN C PRODUCTION BY 40% when it comes on stream in 1989, Takeda noted in a recent release announcing the opening of Midwest and West Coast sales offices. The $90 mil. vitamin C plant, now under construction, will be Takeda's second at its Wilmington, N.C. site. Takeda's first U.S. plant has been producing vitamin B[1] since the fall of 1985. Explaining its reasons for opening new sales offices in Highland Park, Ill. and Newport Beach, Calif., Takeda said that the acquisition last October of Fallek Chemical Company's domestic vitamin and nutritional supplement business has "greatly expanded" Takeda's product line in the U.S. The line expansion is "for the food, pharmaceutical and other industries," Takeda noted. With the Fallek purchase, Takeda acquired a marketing force for its expanding line of bulk vitamin products and tablet excipients. Takeda bought Fallek's food ingredients division in April. Piece by piece Takeda is putting together a corporate infrastructure in the U.S. Separate from Takeda U.S.A.'s bulk vitamin and nutritional product marketing, the Japanese company also has a 50% stake in a Rx pharmaceutical development and marketing arm via its TAP Pharmaceuticals joint venture with Abbott. TAP is marketing Lupron (leuprolide), the firm's first Rx product in the U.S., via its own detail force. Lupron was approved in April 1985 for prostatic cancer with FDA's 1-B rating, which signifies the agency's belief that the drug represents a modest improvement over existing treatments. In the pipeline, TAP has three compounds pending FDA approval: two cephalosporin antibiotics -- Cefmax (cefmenoxime) and Cefonomil (cefsulodin) -- and the sedative estazolam.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
A “basket approach” to phasing out animal testing could help identify areas where “moonshot” research is required to implement new approach methodologies, according to EU industry federation EFPIA.
Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.
Development of the user fee commitment letter largely takes place behind closed doors between industry and FDA. Outside groups see the upcoming negotiation cycle as a chance to change this and other agency information blocks by reminding Commissioner Makary of his commitment to transparency.
